BioNTech SE (22UA.XETRA) Stock Analysis & Winston Score
BioNTech is a German biotechnology company that develops medicines using a technology called mRNA, which teaches the body's cells to fight diseases. It became widely known for co-developing the COVID-19 vaccine with Pfizer, which was one of the first mRNA vaccines ever approved for widespread use. The company focuses on cancer treatments, infectious diseases, and other serious illnesses. BioNTech earns money mainly through product sales and royalties from its COVID-19 vaccine partnership with Pfizer, though vaccine revenues have dropped sharply since the pandemic peak. The company is headquartered in Mainz, Germany, and operates globally, with a strong cash reserve built during the pandemic that funds its ongoing research pipeline. Its biggest growth opportunity is its cancer immunotherapy pipeline, but the main risk is that it has not yet successfully commercialized a second major product, making it heavily dependent on a single revenue source.
Winston Score: 0/100 — Insufficient Data
Not enough data to score this stock reliably.
- Quality: Data not available (0/30)
- Growth: Data not available (0/20)
- Cash Flow: Data not available (0/10)
- Stability: Data not available (0/10)
- Valuation: Data not available (0/10)
- Ownership: Ownership data not available (not counted) (0/15)
